Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

被引：0
|
作者：
Hui, C. [1 ]
Qu, V. [2 ]
Wang, J. Y. [2 ]
Von Eyben, R. [3 ]
Chang, Y. C. [4 ]
Chiang, P. L. [4 ]
Liang, C. H. [4 ]
Lin, J. Y. [4 ]
Lu, J. T. [4 ]
Li, G. [5 ]
Hayden, M. [5 ]
Myall, N. [6 ]
Soltys, S. G. [7 ]
Pollom, E. [3 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Dept Radiat Oncol, Palo Alto, CA 94304 USA
[3] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA
[4] Vysioneer Inc, Cambridge, MA USA
[5] Stanford Canc Inst, Dept Neurosurg, Stanford, CA USA
[6] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA
[7] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2120
引用
收藏
页码：E54 / E55
页数：2
相关论文
共 50 条
  • [41] Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis
    Magnuson, W. J.
    Amini, A.
    Patil, T.
    Kavanagh, B. D.
    Camidge, D. R.
    Braunstein, S. E.
    Boreta, L.
    Attia, A.
    Rana, N.
    Contessa, J. N.
    Gettinger, S. N.
    Lester-Coll, N. H.
    Yu, J. B.
    Chiang, V. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S57 - S58
  • [42] The Effectiveness of Afatinib as First-Line Treatment in Vietnamese Patients With EGFR-Mutant Non-Small Cell Lung Cancer and Brain Metastases
    Van Pham, Thai
    Vu, Thanh Ha
    Nguyen, Hoa Thai Thi
    Pham, Phuong Cam
    Do, Anh Tu
    Nguyen, Tuan Khoi
    Hoang, Thi Anh Thu
    Le, Tuan Anh
    Vuong, Dinh Thy Hao
    Nguyen, Dac Nhan Tam
    Dang, Van Khiem
    Nguyen, Thi Oanh
    Pham, Van Luan
    Nguyen, Minh Hai
    Vo, Thi Huyen Trang
    Mai, Khoa Trong
    Do, Hung Kien
    Nguyen, Thi Thuy Hang
    Trinh, Le Huy
    Nguyen, Hoang Gia
    Truong, Cong Minh
    Pham, Tran Minh Chau
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [43] Predictors of benefit to radiation for oligoprogressive disease in EGFR-mutant metastatic non-small cell lung cancer patients treated with osimertinib
    Chen, Monica F.
    Ma, Jennifer
    Kris, Mark G.
    Gomez, Daniel Richard
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients
    Braune, E. -B.
    Eide, I. J. Zwicky
    Grundberg, O.
    De Petris, L.
    Brustugun, O. T.
    Ekman, S.
    Hydbring, P.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S623 - S623
  • [45] Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
    Patil, Tejas
    Pacheco, Jose M.
    Dimou, Anastasios
    Purcell, William T.
    Rossi, Candice
    Bunn, Paul A.
    Doebele, Robert C.
    Camidge, D. Ross
    Ferrigno, Lisa
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [46] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
  • [47] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [48] Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
    Lemmon, Christopher
    Zabor, Emily Craig
    Pennell, Nathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
    Masip, J. Remon
    Besse, B.
    Aix, S. Ponce
    Perez, A. Callejo
    Al-Rabi, K.
    Caro, R. Bernabe
    Greillier, L.
    Tarruella, M. Majem
    Aransay, N. Reguart
    Monnet, I.
    Cousin, S.
    Lopez, P. Garrido
    Robinet, G.
    Campelo, R. Garciaprime
    Flandin, A-C. Madroszyk
    Mazieres, J.
    Curcio, H.
    Pretzenbacher, Y.
    Dingemans, A-M. C.
    Dziadziuszko, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S35 - S35
  • [50] Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
    Kim, Chul
    Roper, Nitin
    Hoang, Chuong D.
    Szabo, Eva
    Connolly, Maureen
    Padiernos, Emerson
    Kesarwala, Aparna Hemant
    Cultraro, Constance
    Waris, Maryam
    Gao, Shaojian
    Steinberg, Seth M.
    Wong, David T.
    Khan, Laved
    Rajan, Arun
    Guha, Udayan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345